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Alterations of the PI3K/Akt/mammalian target of rapamycin complex 1 (mTORC1)
signaling pathway are causally involved in a subset of malformations of cortical
development (MCDs) ranging from focal cortical dysplasia (FCD) to hemimegalencephaly
and megalencephaly. These MCDs represent a frequent cause of refractory pediatric
epilepsy. The endocannabinoid system -especially cannabinoid CB1 receptor- exerts a
neurodevelopmental regulatory role at least in part via activation of mTORC1 signaling.
Therefore, we sought to characterize the possible contribution of endocannabinoid
system signaling to FCD. Confocal microscopy characterization of the CB1 receptor
expression and mTORC1 activation was conducted in FCD Type II resection samples.
FCD samples were subjected to single nucleotide polymorphism screening for
endocannabinoid system elements, as well as CB1 receptor gene sequencing.
Cannabinoid CB1 receptor levels were increased in FCD with overactive mTORC1
signaling. CB1 receptors were enriched in phospho-S6-positive cells including balloon
cells (BCs) that co-express aberrant markers of undifferentiated cells and dysplastic
neurons. Pharmacological regulation of CB1 receptors and the mTORC1 pathway
was performed in fresh FCD-derived organotypic cultures. HU-210-evoked activation
of CB1 receptors was unable to further activate mTORC1 signaling, whereas CB1
receptor blockade with rimonabant attenuated mTORC1 overactivation. Alterations of
the endocannabinoid system may thus contribute to FCD pathological features, and
blockade of cannabinoid signaling might be a new therapeutic intervention in FCD.
Keywords: cannabinoid, CB1 receptor, malformation of cortical development, corticogenesis, neural progenitor,
cannabinoid, mTORC1, mammalian target of rapamycin
Abbreviations: CAT, chloramphenicol acetyltransferase; DAGL, diacylglycerol lipase; ECS, endocannabinoid system; FAAH,
fatty acid amide hydrolase; FCD, focal cortical dysplasia; MAGL, monoacylglycerol lipase; MCD, malformation of cortical
development; mTORC1, mammalian target of rapamycin complex 1; TSC, tuberous sclerosis complex.
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INTRODUCTION
Malformations of cortical development are associated with
refractory epilepsy in children and young adults (Iﬄand and
Crino, 2017). These alterations are originated by the disruption
of key processes during brain development, such as neural
progenitor cell proliferation or neuronal migration. Within
MCD, some types of FCD and TSC are associated with
overactivation of the mTORC1 signaling pathway (Aronica and
Crino, 2014; Najm et al., 2018). TSC has a clear genetic origin
on loss-of-function mutations of mTORC1 signaling regulators
such as TSC1/TSC2 (hamartin–tuberin), which leads to the
overactivation of mTORC1. Whereas the origin of the different
FCD subtypes is still unclear, recent research has demonstrated
the involvement of alterations of the PI3K/Akt/mTORC1
pathway particularly in FCD Type II (Jansen et al., 2015;
Lim et al., 2015; D’Gama et al., 2017). Characteristic features
of FCD Type II are the presence of balloon cells (BCs)
and cytomegalic neurons with overactive mTORC1 signaling
(usually revealed by the phosphorylation of one of its canonical
targets, the ribosomal protein S6). Hence, FCD Type II cases
are distinguishable at the molecular level from FCD Type
I by the overactivation of mTORC1 signaling. FCD Type
II cases are also distinguishable from Type I cases by the
expression of undifferentiated cell markers in BCs that suggests
a developmental origin (Orlova et al., 2010). Thus, this subtype
of FCDs and hemimegalencephaly are known to be originated
in the dorsal telencephalic progenitors and excitatory projection
neuron lineage (D’Gama et al., 2017; Iﬄand et al., 2018).
Further investigation on the mechanisms responsible for the
epileptogenic network is required for the development of novel
therapeutic strategies aimed to manage FCDs.
The ECS, and especially the cannabinoid CB1 receptor,
exerts an essential neuromodulatory role in the adult brain
via the retrograde lipid messengers 2-arachidonoylglycerol
and anandamide (Soltesz et al., 2015). In addition, CB1
receptors are expressed during human cortical development
(Mato et al., 2003; Wang et al., 2003). During early stages in
brain development, endocannabinoids act as neural cell fate
regulatory cues, and the CB1 receptor is coupled to activation
of the mTORC1 pathway, which allows the control of neural
progenitor identity and pyramidal neuron generation (Díaz-
Alonso et al., 2015). Cannabinoid signaling regulates long-
range axon projection (Mulder et al., 2008; Argaw et al.,
2011; Díaz-Alonso et al., 2012), but also local microcircuits
and interneuron development (Berghuis et al., 2005, 2007).
Moreover, CB1 receptors are required for proper radial migration
during cortical development, and their genetic inactivation
induces brain hyperexcitability (Díaz-Alonso et al., 2017).
Interestingly, transient loss of CB1 receptor function (induced
by pharmacological down-regulation or small-interfering RNA)
during embryonic development exerts long-lasting alterations in
cortical development that result in increased seizure susceptibility
in the adult offspring (de Salas-Quiroga et al., 2015; Díaz-
Alonso et al., 2017). CB1 receptors are expressed in FCD
(Zurolo et al., 2010), but their functional relevance is unclear.
Thus, here we sought to investigate the potential contribution
of aberrant cannabinoid signaling to FCD developmental
pathogenesis.
MATERIALS AND METHODS
Human Samples
The FCD cases included in this study were obtained from the
archives of the Departments of Neuropathology of the Academic
Medical Center (University of Amsterdam, Netherlands), the
University Medical Center in Utrecht (Netherlands), Hospital
Infantil Niño Jesús (Madrid, Spain) and Biobanc de l’Hospital
Infantil Sant Joan de Déu per a la Investigació (Barcelona, Spain)
integrated in the Spanish Biobank Network of ISCIII. A total
of 30 surgical specimens (10 FCD Type I and 20 FCD Type
II), resected from patients undergoing surgery for intractable
epilepsy, were examined (Table 1). Tissue was obtained and used
in accordance with the Declaration of Helsinki and informed
consent was obtained for the use of brain tissue and for access
to medical records for research purposes. All cases were reviewed
TABLE 1 | Clinical features of cortical development alterations in patients analyzed
in this study.
Patient Age range at
surgery
(years)
Duration of
epilepsy
(years)
Diagnosis Location Engel’s
class
1 10 ≤ 15 8 FCD Ia Parietal II
2 15 ≤ 20 10 FCD Ia Frontal I
3 >20 16 FCD Ia Temporal I
4 15 ≤ 20 11 FCD Ia Frontal I
5 >20 17 FCD Ia Temporal I
6 15 ≤ 20 12 FCD Ia Frontal II
7 0 ≤ 5 4 FCD Ia Temporal I
8 0 ≤ 5 3 FCD Ia Frontal I
9 0 ≤ 5 1.5 FCD Ia Multilobar IV
10 0 ≤ 5 2 FCD Ia Frontal I
11 >20 21 FCD IIb Temporal I
12 >20 18 FCD IIb Temporal I
13 >20 19 FCD IIb Frontal I
14 15 ≤ 20 9 FCD IIb Temporal I
15 10 ≤ 15 10 FCD IIb Frontal I
16 0 ≤ 5 5 FCD IIb Multilobar II
17 5 ≤ 10 5 FCD IIb Multilobar III
18 5 ≤ 10 7.5 FCD IIb Frontal II
19 0 ≤ 5 0.5 FCD IIb Multilobar III
20 15 ≤ 20 17 FCD IIb Multilobar II
21 0 ≤ 5 0.5 FCD IIb Multilobar II
22 >20 21 FCD IIb Multilobar III
23 0 ≤ 5 2.5 FCD IIb Temporal I
24 10 ≤ 15 15 FCD IIb Parietal II
25 10 ≤ 15 6 FCD IIb Occipital I
26 5 ≤ 10 5 FCD IIb Frontal I
27 0 ≤ 5 0.5 FCD IIa Occipital II
28 5 ≤ 10 5 FCD IIa Temporal I
29 5 ≤ 10 5 FCD IIa Multilobar I
30 0 ≤ 5 3 FCD IIb Frontal I
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by the corresponding neuropathologist and the diagnosis was
confirmed according to ILAE classification system (Blümcke
et al., 2011; Najm et al., 2018). Control brains from patients
that were not diagnosed with neurologic disorders were also
employed [n = 6; age (years): 53; 40; 34; 21; 51; 25; 58]. Formalin-
fixed, paraffin-embedded tissue (one representative paraffin block
per case containing the complete lesion or the largest part of
the lesion resected at surgery) was sectioned at 6 µm and
mounted on pre-coated glass slides (Star Frost, Waldemar Knittel
GmbH, Barunschweig, Germany). Sections of all specimens
were processed for hematoxylin eosin, luxol fast blue and Nissl
stainings and neuronal and glial markers for classification and
selection.
FCD Neuronal and Organotypic Cultures
Focal cortical dysplasia derived organotypic cultures were
obtained as described (Eugène et al., 2014). In brief, resection
tissue derived from refractory epilepsy surgery of FCD Type
II patients was sliced at 300 µm. Slices were cultured on
a transwell semiporous membrane for 7 days and subjected
to pharmacological regulation. After incubation, slices were
fixed and sectioned for immunofluorescence characterization.
Alternatively, proteins were extracted after cell lysis in a
buffer containing 50 mM Tris, 0.1% Triton X-100, 1 mM
ethylenediaminetetraacetic acid, 1 mM ethylene glycol tetraacetic
acid, 50 mM NaF, 10 mM sodium b-glicerophosphate, 5 mM
sodium pyrophosphate and 1 mM sodium orthovanadate (pH
7.5) supplemented with a protease inhibitor cocktail (Roche,
Basel, Switzerland), 0.1 mM phenylmethane-sulphonylfluoride,
0.1% β-mercaptoethanol and 1 µM microcystin for Western blot
analyses.
CB1 Receptor Promoter Transcriptional
Assays
Embryonic carcinoma P19 cells were employed in reporter assays
as previously described (Díaz-Alonso et al., 2015). Cells were
transfected transiently with a construct encoding the −3016
to +142 sequence (referring to the first nucleotide of exon 1)
of the human CB1 receptor gene promoter fused to the CAT
reporter gene (phCB1-3016-CAT) (Blázquez et al., 2011). The
reporter gene construct was based on the pBLCAT2/pBLCAT3
system, in which the thymidine kinase minimal promoter
was replaced for the human CB1 receptor promoter upstream
of CAT. CAT activity was subsequently analyzed by ELISA
following manufacturer’s instructions (Roche, distributed by
Sigma #11363727001, Madrid, Spain).
Immunofluorescence Microscopy
P19 carcinoma cells, organotypic brain slices and FCD samples
were fixed and immunofluorescence performed. After blockade
with 5% goat serum, overnight incubation at 4◦C with the
indicated primary antibodies was performed: polyclonal
guinea pig anti-CB1 receptor (1:500, Frontier Institute, Japan),
polyclonal rabbit anti-phosphoS235/S236-S6 ribosomal protein
(1:100) and polyclonal rabbit anti-phosphoS240/S244-S6
ribosomal protein (1:800; Cell Signaling Technology, Barcelona,
Spain) and monoclonal mouse anti-c-Myc (1:500; Sigma,
Madrid, Spain). Specificity of CB1 immunoreactivity was
confirmed with an additional polyclonal anti-CB1 antibody
(kindly donated by K. Mackie, Indiana University, Bloomington,
IN, United States). The appropriate anti-mouse, rat, guinea pig,
and rabbit highly cross-adsorbed AlexaFluor 488, AlexaFluor
546, AlexaFluor 594, and AlexaFluor 647 secondary antibodies
(Invitrogen, Carlsbad, CA, United States) were used. Confocal
fluorescence images were acquired by using both Leica TCS-SP2
and LAS-X software (Wetzlar, Germany) with a SP2 or a SP8
microscope, respectively, with three passes by Kalman filter and
a 1024 × 1024 or a 2048 × 2048 collection box, respectively.
Immunofluorescence data were obtained in a blind manner by
an independent observer and sample code remained unsealed
during the whole data processing and analysis. mTORC1
activation status and CB1 immunoreactivity were quantified
in a minimum of 500 cells for each FCD patient or control
sample. Immunoreactivity was measured using Fiji (ImageJ)
software establishing a threshold to measure only specific signal.
The resulting binary mask was then used along the built-in
measure function to acquire the total integrated gray density
among all the pixels inside the binary mask overlayed on top
of the original image. The obtained value was then referred to
the number of DAPI+ cell nuclei present in the optic field. For
in vitro studies, P19 cells (n = 6 independent experiments) and
FCD organotypic cultures (n = 4 independent FCD cases) were
quantified.
Western Blot Assays
Equal amount of protein samples were electrophoretically
separated and transferred to PVDF membranes. After blocking
with 5% BSA, membranes were incubated overnight at 4◦C
with anti-phosphoS235/S236-S6 ribosomal protein (1:1000),
anti-phosphoS240/S244-S6 ribosomal protein (1:1000), anti-
CB1 (1:500) or anti-β-actin (1:5000) primary antibodies. PVDF
membranes were then incubated with the corresponding
secondary antibodies coupled to horseradish peroxidase. Optical
density of the specific immunoreactive band was quantified with
Fiji software. The values of pS6 were normalized to those of
β-actin in the same membranes.
DNA Single Nucleotide Polymorphisms
Analyses and Sequencing
Genomic DNA was obtained by standard methods and
Sequenom SNP analyses were performed by Centro Nacional de
Genotipado (CEGEN-PRB2 USC node, Santiago de Compostela,
Spain) using the iPlex R© Gold chemistry and MassARRAY
platform, according to manufacturer’s instructions (Sequenom,
San Diego, CA, United States). Genotyping assays were designed
using the Sequenom MassARRAY Assay Designer 4.1 software.
SNPs were genotyped in three assays, PCR reactions were set up
in a 5 µl volume and contained 20 ng of template DNA, 1×
PCR buffer, 2 mM MgCl2, 500 µM dNTPs and 1 U/reaction of
PCR enzyme. A pool of PCR primers (Metabion, Steinkirchen,
Germany) was made at a final concentration of each primer
of 100 nM. The thermal cycling conditions for the reaction
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consisted on an initial denaturation step at 94◦C for 2 min,
followed by 45 cycles of 94◦C for 30 s, 56◦C for 30 s and 72◦C
for 1 min, and a final extension step of 72◦C for 1 min. PCR
products were treated with 0.5 U shrimp alkaline phosphatase,
followed by enzyme inactivation to neutralize unincorporated
dNTPs.
The iPLEX GOLD reactions were set up in a final 9 µl
volume and contained 0.222x iPLEX buffer Plus, 1x iPLEX
termination mix and 1x iPLEX enzyme. An extension primer
mix (Metabion) was made to give a final concentration of each
primer between 0.52 µM and 1.57 µM. The thermal cycling
conditions for the reaction included an initial denaturation
step at 94◦C for 30 s, followed by 40 cycles of 94◦C for 5 s,
with an internal five cycles loop at 52◦C for 5 s and 80◦C
for 5 s, followed by a final extension step of 72◦C for 3 min.
The iPLEX Gold reaction products were desalted, dispensed
onto a 384 Spectrochip II using an RS1000 Nanodispenser
and spectra were acquired using the MA4 mass spectrometer,
followed by manual inspection of spectra by trained personnel
using MassARRAY Typer software, version 4.0. All assays were
performed in 384-well plates, including negative controls and
a trio of Coriell samples (Na10830, Na10831, and Na12147)
for quality control. Seven samples were tested in duplicate
and they were 100% concordant. Genomic DNA sequencing
of the CB1 receptor gene coding exon was performed by the
Sanger method under standard conditions by Secugen (Madrid,
Spain).
Data and Statistical Analyses
Results shown represent the means ± SEM, and the number of
experiments is indicated in every case. Statistical analysis was
performed with GraphPad Prism 6.07 (GraphPad Software, La
Jolla, CA, United States) using one-way ANOVA. A post hoc
analysis by the Student–Newman–Keuls test was made (Table 2).
Disease-Genotype association test was performed by the SNPator
online tool (Morcillo-Suarez et al., 2008) to examine genotype
and allele frequencies between patients and controls. P-values of
<0.05 were regarded as statistically significant.
RESULTS
CB1 Cannabinoid Receptor Expression in
FCD Is Associated With Overactive
mTORC1 Pathway
To assess the pathophysiological relevance of CB1 receptor
signaling in MCD we analyzed CB1 receptor immunoreactivity
in control and dysplastic brain areas (Figure 1). FCD cases
(n = 30) were included with a mean patient age of 11.4
years and a male/female distribution of n = 18 and 12,
respectively (Table 1). Double immunofluorescence analysis with
anti-phospho-S6 (recognizing the phosphoS240/S244 sites) and
anti-CB1 antibodies confirmed the selective overactivation of
the mTORC1 pathway in FCD Type II but not FCD Type I
samples (Figures 1A,B). Quantification of CB1 immunoreactivity
revealed that receptor expression is notably enriched in the
TABLE 2 | Statistical analyses.
Figure Comparison Statistic value Significance
Figure 1A One-way ANOVA F = 22.57 ∗∗∗∗
FCDI vs. Co q = 1.930 ns
FCDII vs. Co q = 7.833 ∗∗∗∗
FCDII vs. FCDI q = 7.005 ∗∗∗∗
Figure 1B One-way ANOVA F = 24.87 ∗∗∗∗
FCDI vs. Co q = 1.013 ns
FCDII vs. Co q = 8.856 ∗∗∗∗
FCDII vs. FCDI q = 7.271 ∗∗∗∗
Figure 1C One-way ANOVA F = 24.87 ∗∗∗∗
FCDI vs. Co q = 0.7072 ns
FCDII vs. Co q = 7.399 ∗∗∗∗
FCDII vs. FCDI q = 8.187 ∗∗∗∗
Figure 3A One-way ANOVA F = 8.749 ∗∗
RHEB vs. pCAG-GFP q = 4.450 ∗∗
shTSC2 vs. shCo q = 5.700 ∗∗
Figure 3B One-way ANOVA F = 2.917 ∗
Tbr2 vs. GFP q = 5.083 ∗∗
Figure 5A One-way ANOVA F = 16.77 ∗∗∗
RAPA vs. VEH q = 7.675 ∗∗∗
RAPA vs. HU-210 q = 6.139 ∗∗
Figure 5B One-way ANOVA F = 7.305 ∗∗∗
HU-210 vs. VEH q = 0.2946 ns
SR1 vs. VEH q = 4.164 ∗
RAPA vs. VEH q = 5.153 ∗∗
HU-210 + SR1 vs. VEH q = 5.208 ∗∗
One-way ANOVA followed by Student–Newman–Keuls post hoc test. Statistical
significance ∗∗∗∗p < 0.0001; ∗∗∗p < 0.001; ∗∗p < 0.01; ∗p < 0.05; ns, non-
significant.
dysplastic areas of FCD Type II when compared with control
brain tissue, but not in FCD Type I (Figures 1A,C). A more
detailed analysis of double immunofluorescence images showed
that CB1-positive cells largely colocalized with phospho-S6
immunoreactivity in FCD Type II, and CB1+pS6+ cells were
highly enriched in the dysplastic areas when compared to
control cortical tissue (Figure 1D). Equivalent findings of
CB1 enrichment in phospho-S6-positive cells were reproduced
when using as alternative readout, anti phosphoS235/S236-S6
antibody (Supplementary Figure 1). Moreover, the intensity of
phospho-S6 immunoreactivity was selectively increased when
comparing FCD Type II and I (1.61 ± 0.14 versus 1.00 ± 0.07,
respectively; p < 0.05, n = 4). Next, we analyzed CB1 receptor
expression in BCs and dysplastic neurons based in morphological
characterization and mTORC1 overactivation (Figure 2A). This
indicated that 2.43 ± 0.92 and 0.57 ± 0.29% of total CB1 tissue
immunoreactivity corresponded to these cell subpopulations,
respectively. FCD Type II is characterized by the expression
of undifferentiated markers in BC including Sox2, Oct4, Pax6,
Tbr1, Otx1, and others (Hadjivassiliou et al., 2010; Orlova et al.,
2010; Arai et al., 2012; Yao et al., 2016). Thus, we analyzed the
expression of CB1 receptors in FCD Type II neurons together
with undifferentiated-cell markers. Whereas in FCD Type II
sparse c-Myc-positive cells could be detected, this was never the
case in the FCD Type I samples. Importantly, c-Myc-positive cells
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FIGURE 1 | The CB1 receptor is enriched in focal cortical dysplasia (FCD) Type II in cells with overactive mTORC1 signaling. (A) Representative immunofluorescence
images showing the presence of CB1 receptors in samples from Type I and II FCD and control brains, revealed with an anti-CB1 antibody (red). Cells with over-active
mTORC1 signaling are stained with phospho-S6Ser240/244 antibody (green). High magnification images of CB1 receptor expression associated with mTORC1
overactivation in FCD Type II are shown. (B,C) Phospho-S6+ cells and CB1 receptor immunoreactivity (IR) were quantified in the dysplastic area and referred to total
cell number (DAPI counterstaining). Control, FCD Type I and FCD Type II cases (B, n = 4, 7 and 18, respectively; C, n = 6, 8, 13). (D) CB1+ phospho-S6+
double-labeled cells were quantified and referred to total pS6+ cells. Control, FCD Type I and FCD Type II cases (n = 4, 7, and 18, respectively). Statistical
comparison versus control samples, ∗∗∗∗p < 0.0001; statistical comparison versus FCD Type I samples, ####p < 0.0001. Scale bar 45 µm, insets, 10 µm.
expressed CB1 receptors and showed active mTORC1 signaling
(pS6+) (Figure 2B). Hence, in FCD Type II we determined
that 72.74 ± 11.04% c-Myc-positive cells were also phospho-S6
positive.
CB1 Cannabinoid Receptor Expression Is
Not Induced by mTORC1 Signaling
To determine if CB1 receptor enrichment in FCD lesions was a
cause or a consequence of mTORC1 overactivation we analyzed if
this signaling pathway can regulate CB1 receptor expression. P19
cells were transfected with a plasmid encoding a constitutively
active mutant of the mTORC1 upstream activator Rheb
(RhebQ64L) or a Tsc2 specific short-hairpin RNA coding plasmid
(shTSC2). In these conditions, as compared to control cells,
mTORC1 pathway activity increased as evidenced by the strong
increase of pS6+ immunoreactive cells (Figure 3A). However,
under the same conditions of overactive mTORC1 signaling,
CB1 receptor protein levels were not induced (Figure 3B).
We also performed CB1 promoter transcriptional assays by co-
transfection with a CAT gene reporter in frame with a minimal
CNR1 promoter (Blázquez et al., 2011). Again, in cells with
overactive mTORC1 pathway CB1 promoter activity was not
induced (Figure 3C). As a control of the sensitivity of this
assay, P19 cells were transfected with the intermediate progenitor
transcription factor Tbr2 (Eomes). The CB1 promoter has several
putative Tbr2-binding sites [Table 3, Matinspector (Genomatix)],
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FIGURE 2 | CB1 receptors are present in undifferentiated cells. (A) Dysplastic
neurons (A1,A1′,A1′ ′ ) and balloon cells (A2,A2′,A2′ ′) were identified based in
morphological criteria in hematoxylin/eosin sections stained with NeuN
antibody (A1,A2). CB1 receptor expression and mTORC1 activity status were
analyzed by immunofluorescence with CB1 and phospho-S6 antibodies,
respectively (A1′,A1′ ′,A2′,A2′ ′). (B) Representative immunofluorescence
images showing the presence of CB1 receptor (red) in FCD Type II brain cells
labeled with the undifferentiated cell marker c-Myc (blue) and active mTORC1
signaling phospho-S6+ cells (green). High magnification insets are shown
(lower panels). Scale bar: 25 µm, insets, 10 µm.
and its expression was indeed sufficient to increase CB1 promoter
reporter activity (Figure 3C), but failed to increase protein levels
(Figure 3B). In summary, these results indicate that the increased
CB1 receptor levels in FCD are not a direct consequence of an
overactive mTORC1 pathway.
Genetic Characterization of the
Endocannabinoid System in FCD
The observation that CB1 receptor levels are increased in
the dysplastic cells of FCD Type II cases prompted us to
expand the analyses to other elements of the ECS that may
contribute to cannabinoid signaling deregulation. Genomic DNA
and messenger RNA from the FCD collection were obtained.
Real time PCR expression analysis confirmed increased levels
of CB1 receptor transcripts in FCD Type II versus control
brain extracts (Table 4), further supporting the results obtained
at the protein level by immunofluorescence characterization
(Figure 1). Transcript levels of other elements of the ECS
[DAGL alpha and beta isoforms, MAGL, FAAH and N-acyl
phosphatidylethanolamine phospholipase D (NAPE-PLD)] were
also quantified and no differences were observed (Table 4).
To further characterize if cannabinoid signaling alterations
may contribute to overactive mTORC1 in FCD Type II,
we performed single nucleotide polymorphism (SNP) analysis
of various genes of the ECS including the CB1 receptor,
DAGL alpha and beta, MAGL, FAAH and CB2 receptor
(Supplementary Table 1). A total 48 SNPs of the ECS were
selected, based on previous evidences that point to their potential
involvement in different nervous system disorders. Genotype
disease association analysis revealed the existence of three
polymorphisms in the DAGLA gene differentially expressed in
FCD Type II versus control specimens (Table 5). The rest of
SNPs analyzed for CNR1, DAGLB, MAGL, FAAH, and CNR2
did not show any difference between pathologic samples and
controls. To further investigate the potential involvement of
CB1 receptors in FCD we sequenced the CNR1 gene exon
in the FCD and control genomic DNA samples. CNR1 exon
1 sequencing revealed normal wild-type sequence in most
samples and only rs1049353 SNP (c.1359G>A; p.Thr453) was
identified with similar distribution among dysplastic and control
DNA.
In summary, these results suggest that the DAGLα-evoked
generation of the endocannabinoid 2-AG might be altered in
FCD Type II and can contribute to its etiopathology. However,
the exact contribution of endocannabinoid tone alterations in
MCD would require more complex genetic studies to identify its
potential association with the origin of the disease.
CB1 Cannabinoid Receptor Crosstalk
With the mTORC1 Pathway in FCD
Resections
Additional specimens derived from surgical resection for
intractable epilepsy were analyzed ex vivo for mechanistic studies.
3T magnetic resonance imaging (MRI), fluorodeoxyglucose
(FDG)-PET scan, scalp electroencephalography (EEG) recording
and invasive neurophysiological studies were employed
to identify the origin of epileptic seizures (Figure 4A).
Representative images of one case prior and after surgery
are shown. In this particular patient, a 5-year-old male, a small
FCD Type II involving the left rolandic region and superior
frontal gyrus (arrowheads, Figure 4A) was associated with daily
focal motor seizures and Epilepsia Partialis Continua involving
the left arm and the face. Scalp EEG analyses revealed continuous
focal epileptiform discharges (arrowhead, Figure 4B) in
accordance with a hypermetabolic FDG-PET focus. Intracraneal
EEG exploration of the dysplastic lesion, using a combination
of subdural electrodes and depth electrodes, better defined a
characteristic EEG pattern, indicative of FCD. This characteristic
EEG pattern shows continuous repetitive burst of epileptiform
activity turning into focal EEG ictal patterns (arrowhead,
Figure 4C), in association with the onset of clinical seizure
signs. After tailored resection of the epileptogenic zone, 1 year
follow-up after surgery revealed a seizure-free clinical status,
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FIGURE 3 | The mTORC1 pathway does not regulate CB1 receptor expression. (A) Characterization of mTORC1 activation in P19 cells after transfection with the
Rheb constitutive active mutant Q64L, shTSC2, a scrambled shRNA encoding vector (shCo), or GFP encoding plasmid. mTORC1 activation was analyzed by means
of phospho-S6-positive cells quantification. Scale bar: 50 µm. (B) Western blot analysis of CB1 receptor levels in the same conditions as above. Representative
immunoblot luminograms for CB1 and β-actin as loading control are shown and quantification is provided (mean ± SEM, n = 3). (C) CB1 receptor promoter activity
was analyzed using a CAT construct 24 h after transfection (n = 6). Statistical comparison versus the corresponding control samples, ∗∗p < 0.01.
MRI and EEG showed absence of the lesion and normalization
of hyperexcitability.
Considering the regulatory role of CB1 receptors in cortical
progenitor cell identity via mTORC1 signaling (Díaz-Alonso
et al., 2015), we next sought to investigate the impact of
the receptor in FCD-derived neurons. We obtained FCD
Type II organotypic cultures derived from fresh resections
that were maintained for 7 days in vitro and subjected to
pharmacological manipulation. Quantification of phospho-S6
immunoreactivity revealed that CB1 receptor activation with the
cannabinoid agonist HU-210 was without effect on mTORC1
activation, whereas the mTORC1 inhibitor rapamycin was
effective in reducing mTORC1 overactivation (Figure 5A).
Western blot analysis confirmed that CB1 receptor agonism
did not influence mTORC1 activation, whereas the CB1
inverse agonist SR141716 (rimonabant), as well as rapamycin,
reduced mTORC1 activation as assessed by phosphoS240/244-S6
levels (Figure 5B). Equivalent results were obtained with
the alternative phosphoS235/236-S6 antibody (Supplementary
Figure 2). Overall, these results indicate that inhibition, but not
activation of the CB1 receptor, may tune the overactive mTORC1
pathway found in FCD Type II dysplastic brain.
DISCUSSION
In the present study, we characterized the expression and
function of the ECS to assess its potential contribution to the
Frontiers in Pharmacology | www.frontiersin.org 7 January 2019 | Volume 9 | Article 1508
fphar-09-01508 January 2, 2019 Time: 18:19 # 8
García-Rincón et al. Cannabinoid Signaling in Focal Cortical Dysplasia
TABLE 3 | Putative Tbr2 (Eomes) binding sites in the Cnr1 locus identified using
MatInspector software.
Species Gene
location
Binding site position Strand Matrix
similarity
Start End
Human 6q15 88164872 88164900 + 0.941
88166737 88166765 + 0.963
88166645 88166673 + 0.989
88166554 88166568 + 0.902
88168289 88168317 + 0.99
Mouse 4A5 33936594 33936608 − 0.896
33925880 33925908 + 0.901
33944561 33944589 − 0.999
TABLE 4 | Endocannabinoid system elements analyzed by qPCR in FCD Type II
and control samples.
Transcript Condition Mean SEM Significance
CB1 Control 1.00 0.2397 ∗
FCDII 33.70 5.3080
DAGLα Control 1.00 0.0004 ns
FCDII 0.45 0.1286
DAGLβ Control 1.00 0.0106 ns
FCDII 0.84 0.2274
MAGL Control 1.00 0.0005 ns
FCDII 0.88 0.3061
NAPE-PLD Control 1.00 0.0264 ns
FCDII 0.72 0.1176
FAAH Control 1.00 0.0182 ns
FCDII 0.36 0.1910
Statistical comparison versus control tissue ∗p < 0.05. CB1 transcript (n = 4 and
22, control and FCDII), other endocannabinoid system elements (n = 4 and 8
control and FCDII).
etiopathology of MCDs, in particular FCD Type II. Our results
reveal a striking increase in CB1 receptor expression levels in FCD
Type II, and this enrichment occurs in neurons with overactive
mTORC1 signaling. In addition, characterization of genomic
DNA in the dysplastic brain resections showed an enrichment of
three SNPs in the DAGLA gene in FCD Type II versus controls.
The SNPs analyzed in other ECS element genes did not show any
difference between groups. In addition, sequencing of the CNR1
coding exon did not reveal any SNP or mutation differentially
present in FCD Type II versus control brains.
Presynaptic CB1 receptors engaged by retrograde
endocannabinoid messengers constitute an efficient regulatory
mechanism of excessive neurotransmitter release. Hence,
endocannabinoid signaling is a crucial pathway controlling
neuronal activity and its activation or blockade modulates
seizures and epilepsy development (Soltesz et al., 2015). Patients
of temporal lobe epilepsy have decreased CB1 receptor expression
(Ludányi et al., 2008; Goffin et al., 2011). Likewise, selective loss
of function of presynaptic CB1 receptors in projection neuron
populations of the mouse brain results in an imbalance of the
excitatory/inhibitory tone and a higher susceptibility to seizures
FIGURE 4 | EEG characterization of a representative FCD case subject to
surgery. (A) FDG-PET scan co-registered with 3T MRI of a 5-year-old child
affected by a “malignant rolandic epilepsy” with daily motor seizures and
Epilepsia Partialis Continua. Hypermetabolic FDG-PET focus (arrowheads).
Small focal cortical dysplasia involving the left rolandic region and superior
frontal gyrus (arrowhead) and MRI 1 year after epilepsy surgery. (B,C) Scalp
and intracraneal EEG recording, respectively, of the previous patient, using a
combination of subdural electrodes and depth electrodes, prior resection of
the epileptogenic zone. Arrowheads, indicate epileptiform activity.
(Monory et al., 2006). Thus, the enrichment in CB1 receptor
expression in FCD lesions could represent a compensatory
mechanism to attenuate the imbalance of excitatory/inhibitory
neuronal activity. In addition, gene expression assays indicate
that, at least for the hCB1 receptor promoter employed (−3016
to +142 bp sequence), is not directly induced by overactive
mTORC1 pathway, indicating that other signaling events control
CB1 receptor expression in this context.
SNPs analyses and genomic DNA sequencing of the CNR1
exon did not reveal any mutation associated with FCD Type II.
Alternatively, the potential involvement of 2-AG metabolism
in FCD Type II is suggested by the existence of a selective
enrichment in three SNPs of the DAGLA gene. The impact
of the DAGLA SNPs found in our study in 2AG production
or DAGL regulation, is yet unknown as they correspond to
non-coding regions. Nevertheless DAGLA transcript levels were
slightly reduced in FCD when compared to control tissue. These
results are in agreement with a recent study that found DAGLA
polymorphisms associated with neurodevelopmental disorders
and seizures (Smith et al., 2017), while CB1 receptor associated
with pain sensitivity, sleep, memory or anxiety, but not seizures.
CB1 receptors are coupled to the mTORC1 signaling pathway
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TABLE 5 | SNPs analyzed in Focal cortical dysplasia Type II and control brain genomic DNA extracts.
SNP Alleles Major allele homozygous (%) Heterozygous (%) Minor allele homozygous (%) Disease
association
Major/Minor Controls FCD Controls FCD Controls FCD
rs806365 C/T 20.0 36.4 70.0 45.4 10.0 18.2
rs7766029 T/C 20.0 31.8 50.0 54.5 30.0 13.6
rs806366 T/C 40.0 31.8 40.0 31.8 20.0 36.4
rs806368 T/C 60.0 54.5 20.0 36.4 20.0 9.0
rsl2720071 A/G 60.0 86.4 40.0 13.6 0.0 0.0
rs4707436 G/A 60.0 59.1 30.0 40.9 10.0 0.0
rsl049353 G/A 80.0 68.2 10.0 31.8 10.0 0.0
rs806369 C/T 60.0 45.5 30.0 40.9 10.0 13.6
rs2023239 T/C 60.0 63.6 40.0 36.4 0.0 0.0
rsl535255 T/G 70.0 63.6 30.0 36.4 0.0 0.0
rs806379 A/T 30.0 18.2 60.0 77.3 10.0 4.5
rs9444584 C/T 60.0 54.5 30.0 45.5 10.0 0.0
rs9450898 C/T 70.0 63.6 30.0 36.4 0.0 0.0
rs806380 A/G 60.0 54.5 30.0 40.9 10.0 4.5
rs6454674 T/G 40.0 63.6 40.0 31.8 20.0 4.5
rs2180619 A/G 30.0 31.8 50.0 45.5 20.0 22.7
rs4963304 G/A 10.0 68.2 50.0 31.8 40.0 0.0 ∗
rs7931563 T/G 50.0 40.9 50.0 40.9 0.0 18.2
rs7942387 C/A 90.0 100.0 10.0 0.0 0.0 0.0
rsl98430 C/T 30.0 77.3 40.0 22.7 30.0 0.0 ∗
rsl98444 T/C 40.0 4.5 60.0 45.5 0.0 50.0 ∗
rs34365114 G/A 100.0 95.5 0.0 4.5 0.0 0.0
rsl44674730 C/T 100.0 100.0 0.0 0.0 0.0 0.0
rsl43650244 AAA/- 90.0 100.0 10.0 0.0 0.0 0.0
rsl87296513 C/T 100.0 100.0 0.0 0.0 0.0 0.0
rs3813518 G/A 50.0 77.3 50.0 18.2 0.0 4.5
rs3813517 A/G 100.0 95.5 0.0 4.5 0.0 0.0
rs836559 C/G 10.0 36.4 40.0 45.4 50.0 18.2
rs2303361 T/C 40.0 72.8 30.0 22.7 30.0 4.5
rs76802560 G/T 100.0 100.0 0.0 0.0 0.0 0.0
rs6801421 G/A 90.0 63.6 10.0 36.4 0.0 0.0
rs72969613 C/T 100.0 100.0 0.0 0.0 0.0 0.0
rs4881 A/G 70.0 81.8 20.0 18.2 10.0 0.0
rsll5970931 A/G 100.0 100.0 0.0 0.0 0.0 0.0
rs932816 G/A 80.0 50.0 20.0 45.5 0.0 4.5
rs4141964 G/A 30.0 40.9 30.0 40.9 40.0 18.2
rs324420 C/A 30.0 59.1 50.0 22.7 20.0 18.2
rs324419 G/A 80.0 81.8 20.0 18.2 0.0 0.0
rs2295632 C/A 30.0 54.5 40.0 27.3 30.0 18.2
rsl2029329 G/C 30.0 54.5 40.0 27.3 30.0 18.2
rsl2744386 C/T 10.0 31.8 70.0 50.0 20.0 18.2
rsll30321 A/G 20.0 27.3 80.0 54.5 20.0 18.2
rsll06 G/C 20.0 27.3 80.0 54.5 20.0 18.2
rs2229579 C/T 70.0 63.6 30.0 27.3 0.0 9.1
rs2501431 A/G 20.0 27.3 80.0 54.5 20.0 18.2
rs41311993 G/T 100.0 100.0 0.0 0.0 0.0 0.0
rs35761398 CC/TT 20.0 23.8 80.0 57.2 20.0 19.0
rs2501432 C/T 20.0 27.3 80.0 54.5 20.0 18.2
Major and minor allele’s distribution in control and focal cortical dysplasia (FCD) Type II. Disease association ∗p < 0.05.
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FIGURE 5 | CB1 receptors blockade attenuates mTORC1 overactivation in FCD organotypic cultures. Organotypic cultures of FCD resections were cultured 7 days
in vitro and exposed to the CB1 receptor agonist HU-210 (1 µM), and rapamycin (1 µM) 90 min. (A) Representative images of immunofluorescence characterization
with phospho-S6S240/244 antibody were quantified and phosphoS6 immunoreactivity was referred to the total number of cells revealed by DAPI counterstaining.
(B) Western blot analysis of phospho-S6S240/244 levels was performed in slice extracts after 90 min incubation with HU-210 alone or together with SR141716
(25 µM), SR141716 or rapamycin (n = 4 experiments). Statistical comparison versus vehicle samples, ∗p < 0.05; ∗∗p < 0.01. Scale bar: 80 µm.
at early stages of neocortex formation (Díaz-Alonso et al., 2015)
as well as in the adult brain (Puighermanal et al., 2009). We
therefore analyzed CB1 receptor downstream signaling in
FCD-derived organotypic slices. The CB1 agonist HU-210
was unable to further increase mTORC1 activation, reflecting
that the pathway is already overactive. Remarkably, the CB1
inverse agonist rimonabant was efficient in reducing phospho-
S6 levels. This is of interest, as dampening overactive CB1
receptor activity with rimonabant in other settings as the Fmr1
knockout mice efficiently decreases exacerbated mTORC1
activity and symptoms (Busquets-Garcia et al., 2013). Thus,
these results point to a basal cannabinoid signaling tone
that sustains exacerbated mTORC1 activity in FCD Type II.
The ribosomal S6 protein is regulated by phosphorylation
at multiple sites (Meyuhas, 2015). S6 phosphorylation at
Ser240/244 is selectively mediated by S6K1/2 providing a better
readout of mTORC1 upstream activation, while Ser235/236
phosphorylation is regulated by different signaling pathways
(cAMP/PKA, casein kinase 1, MAPK-activated protein kinase-1
and mTORC1/S6K1/2). Initial studies revealed increased levels
of phosphoS235/236-S6 protein in FCD and TSC (Baybis et al.,
2004; Aronica et al., 2007). More recently, somatic mutations
of MTOR signaling pathway and other upstream regulators
PI3K/Akt, TSC1, TSC2, DEPDC5 have been demonstrated
in FCD Type II (Jansen et al., 2015; Lim et al., 2015; Ricos
et al., 2016). Hence, phosphorylation of S6 protein by different
mechanisms may have different functional consequences in FCD
and may differ among neural cell types (Ljungberg et al., 2006;
Biever et al., 2015). Considering the finding that CB1 receptor
antagonism attenuates the phosphorylation of the ribosomal S6
protein at different amino acids (Ser235/236 and Ser240/244)
it can be predicted that different CB1 downstream signaling
effectors: cyclic AMP-mediated and cAMP-independent
(PI3K/Akt-mediated) contribute to its regulation. Hence,
regulation of cannabinoid signaling constitutes and attractive
target for various mTOR-associated disorders and symptoms -the
so-called “mTORopathies”. Cannabidiol, a non-psychotomimetic
cannabinoid with multiple targets, marketed as Epidiolex (GW
Pharma), has demonstrated its efficacy as antiepileptic drug in
refractory epilepsy including TSC, Dravet and Lennox-Gastaut
syndromes, and is under clinical trial for FCDs (Devinsky et al.,
2015; Hess et al., 2016; Thiele et al., 2018).
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Interestingly, FCD type II is believed to be originated
from the dorsal telencephalic progenitor cell compartment
and their excitatory neuronal progeny (D’Gama et al., 2017).
Noteworthy, in mTORopathies experimental models of MCDs
unbalanced deep and upper layer neuronal development
occurs as consequence of aberrant expression of neural fate
determinants. Hence, a contribution of CB1 receptor signaling
to neural precursor alterations responsible for FCD Type
II cannot be excluded. The consequences of CB1 receptor
activity during development and later in the adult brain
can be intrinsically different. During embryonic development,
CB1 receptor controls radial glial to intermediate progenitor
cell transition via mTORC1 signaling (Díaz-Alonso et al.,
2015), and later, at postmitotic stages, tunes deep cortical
neuronal differentiation (Mulder et al., 2008; Díaz-Alonso et al.,
2012). Thus, CB1 receptor activity during embryonic stages
controls progenitor proliferation and neuronal differentiation,
and alterations in cannabinoid signaling have the potential
to evoke long-term neuronal plasticity and abnormalities
underlying FCD neuronal hyperexcitability. In animal models,
conditional ablation of the CB1 receptor during embryonic
development results in increased RhoA levels, ectopic neuron
accumulations and increased seizure susceptibility (Díaz-Alonso
et al., 2017). Noteworthy, RhoA knockdown prevents brain
hyperexcitability and projection neuron alterations induced by
CB1 receptor ablation. Therefore, either hyper- or hypoactive
endocannabinoid signaling during cortical development can be
responsible for neuronal differentiation and positioning deficits
contributing to MCDs. Later, in adult brain, when neuronal
activity is established, the neuromodulatory function of the
ECS takes place. The precise consequences of CB1 receptor
activity in the hyperexcitability neuronal circuit of the dysplastic
brain remain unknown. Among other mechanisms involved in
FCD, decreased hyperpolarization-activated non-specific cation
currents contribute to pyramidal layer V hyperexcitability
(Albertson et al., 2011). Interestingly, a particular pool of
somatodendritic CB1 receptors can regulate Ih currents and this
explains in turn some of the cognitive consequences of CB1
signaling (Maroso et al., 2016).
This study highlights the pathological implications of
altered developmental cannabinoid signaling in refractory
epilepsy. Characterization of epileptogenic FCD tissue from
palliative surgery and dysplastic-derived organotypic cultures
indicates that increased CB1 receptor signaling may constitute
a compensatory mechanism to counteract FCD Type II
hyperexcitability, and its antagonism can dampen mTORC1
overactivation. We anticipate that in the near future new
genetic linkage association analyses using larger cohorts of
patients with pediatric epilepsy could provide further support
to cannabinoid signaling deregulation as a causal mechanism
underlying refractory epilepsy.
ETHICS STATEMENT
This study was carried out in accordance with the
recommendations of “Hospital Universitario Niño Jesús
Madrid, Ethic committee” with written informed consent from
all subjects. All subjects gave written informed consent in
accordance with the Declaration of Helsinki. The protocol was
approved by the “Ethic committee of Hospital Universitario Niño
Jesús Madrid”.
AUTHOR CONTRIBUTIONS
DG-R, JD-A, ZO, AdS-Q, JP-L, JA, and CJ obtained the samples,
processed them, and performed the experiments. IdP, VM-C, EA,
and MP-J were in charge of resection handling and determination
of the dysplastic areas that were analyzed. MG, MP-J, and IG-R
designed the study, analyzed the data, and wrote the manuscript.
FUNDING
This study was funded by Instituto de Salud Carlos III (#PI15-
0310 #PI18-00941, Plan Estatal de I+D+i to IG-R) and co-
financed by the European Development Regional Fund “A way
to achieve Europe” (EDRF), Spanish Ministerio de Economía y
Competitividad (co-funded by the EDRF in the Framework of the
Operative Program “Reinforcement of Research, Technological
Development and Innovation” RTC-2015-3364-1 to IG-R and
MINECO/FEDER, grant SAF2015-64945-R to MG). EA is
supported by EPISTOP (grant 603291). JD-A was supported by
a PFIS program fellowship co-financed by the European Social
Fund “El FSE invierte en tu futuro” (ESF). DG-R, AdS-Q, JP-L,
and JA were supported by Fundación Tatiana Pérez de Guzmán
el Bueno (DG-R) and Ministerio de Educación, Cultura y Deporte
(FPU program), respectively. The genotyping service was carried
out at CEGEN-PRB2-ISCIII, it is supported by grant PT13/0001,
ISCIII-SGEFI / FEDER.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fphar.
2018.01508/full#supplementary-material
REFERENCES
Albertson, A. J., Yang, J., and Hablitz, J. J. (2011). Decreased hyperpolarization-
activated currents in layer 5 pyramidal neurons enhances excitability in focal
cortical dysplasia. J. Neurophysiol. 106, 2189–2200. doi: 10.1152/jn.00164.
2011
Arai, A., Saito, T., Hanai, S., Sukigara, S., Nabatame, S., Otsuki, T.,
et al. (2012). Abnormal maturation and differentiation of neocortical
neurons in epileptogenic cortical malformation: unique distribution
of layer-specific marker cells of focal cortical dysplasia and
hemimegalencephaly. Brain Res. 1470, 89–97. doi: 10.1016/j.brainres.2012.
06.009
Frontiers in Pharmacology | www.frontiersin.org 11 January 2019 | Volume 9 | Article 1508
fphar-09-01508 January 2, 2019 Time: 18:19 # 12
García-Rincón et al. Cannabinoid Signaling in Focal Cortical Dysplasia
Argaw, A., Duff, G., Zabouri, N., Cécyre, B., Chainé, N., Cherif, H., et al. (2011).
Concerted action of CB1 cannabinoid receptor and deleted in colorectal cancer
in axon guidance. J. Neurosci. 31, 1489–1499. doi: 10.1523/JNEUROSCI.4134-
09.2011
Aronica, E., Boer, K., Baybis, M., Yu, J., and Crino, P. (2007). Co-expression of
cyclin D1 and phosphorylated ribosomal S6 proteins in hemimegalencephaly.
Acta Neuropathol. 114, 287–293. doi: 10.1007/s00401-007-0225-6
Aronica, E., and Crino, P. B. (2014). Epilepsy related to developmental tumors
and malformations of cortical development. Neurotherapeutics 11, 251–268.
doi: 10.1007/s13311-013-0251-0
Baybis, M., Yu, J., Lee, A., Golden, J. A., Weiner, H., McKhann, G., et al. (2004).
mTOR cascade activation distinguishes tubers from focal cortical dysplasia.
Ann. Neurol. 56, 478–487. doi: 10.1002/ana.20211
Berghuis, P., Dobszay, M. B., Wang, X., Spano, S., Ledda, F., Sousa, K. M., et al.
(2005). Endocannabinoids regulate interneuron migration and morphogenesis
by transactivating the TrkB receptor. Proc. Natl. Acad. Sci. U.S.A. 102, 19115–
19120. doi: 10.1073/pnas.0509494102
Berghuis, P., Rajnicek, A. M., Morozov, Y. M., Ross, R. A., Mulder, J., Urban,
G. M., et al. (2007). Hardwiring the brain: endocannabinoids shape neuronal
connectivity. Science 316, 1212–1216. doi: 10.1126/science.1137406
Biever, A., Puighermanal, E., Nishi, A., David, A., Panciatici, C., Longueville, S.,
et al. (2015). PKA-dependent phosphorylation of ribosomal protein S6 does not
correlate with translation efficiency in striatonigral and striatopallidal medium-
sized spiny neurons. J. Neurosci. 35, 4113–4130. doi: 10.1523/JNEUROSCI.
3288-14.2015
Blázquez, C., Chiarlone, A., Sagredo, O., Aguado, T., Pazos, M. R., Resel, E., et al.
(2011). Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor
in huntington’s disease. Brain 134, 119–136. doi: 10.1093/brain/awq278
Blümcke, I., Thom, M., Aronica, E., Armstrong, D. D., Vinters, H. V., Palmini, A.,
et al. (2011). The clinicopathologic spectrum of focal cortical dysplasias: a
consensus classification proposed by an ad hoc task force of the ILAE diagnostic
methods commission. Epilepsia 52, 158–174. doi: 10.1111/j.1528-1167.2010.
02777.x
Busquets-Garcia, A., Gomis-González, M., Guegan, T., Agustín-Pavón, C.,
Pastor, A., Mato, S., et al. (2013). Targeting the endocannabinoid system in the
treatment of fragile X syndrome. Nat. Med. 19, 603–607. doi: 10.1038/nm.3127
de Salas-Quiroga, A., Díaz-Alonso, J., García-Rincón, D., Remmers, F., Vega, D.,
Gómez-Cañas, M., et al. (2015). Prenatal exposure to cannabinoids evokes long-
lasting functional alterations by targeting CB 1 receptors on developing cortical
neurons. Proc. Natl. Acad. Sci. 112, 13693–13698. doi: 10.1073/pnas.1514962112
Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., et al.
(2015). Cannabidiol in patients with treatment-resistant epilepsy: an open-label
interventional trial. Lancet Neurol. 15, 270–278. doi: 10.1016/S1474-4422(15)
00379-8
D’Gama, A. M., Woodworth, M. B., Hossain, A. A., Bizzotto, S., Hatem, N. E.,
LaCoursiere, C. M., et al. (2017). Somatic mutations activating the mTOR
pathway in dorsal telencephalic progenitors cause a continuum of cortical
dysplasias. Cell Rep. 21, 3754–3766. doi: 10.1016/j.celrep.2017.11.106
Díaz-Alonso, J., Aguado, T., de Salas-Quiroga, A., Ortega, Z., Guzmán, M.,
and Galve-Roperh, I. (2015). CB1 cannabinoid receptor-dependent activation
of mTORC1/Pax6 signaling drives Tbr2 expression and basal progenitor
expansion in the developing mouse cortex. Cereb. Cortex 25, 2395–2408. doi:
10.1093/cercor/bhu039
Díaz-Alonso, J., Aguado, T., Wu, C.-S., Palazuelos, J., Hofmann, C., Garcez, P.,
et al. (2012). The CB(1) cannabinoid receptor drives corticospinal motor
neuron differentiation through the Ctip2/Satb2 transcriptional regulation axis.
J. Neurosci. 32, 16651–16665. doi: 10.1523/JNEUROSCI.0681-12.2012
Díaz-Alonso, J., De Salas-Quiroga, A., Paraíso-Luna, J., García-Rincón, D., Garcez,
P. P., Parsons, M., et al. (2017). Loss of cannabinoid cb1receptors induces
cortical migration malformations and increases seizure susceptibility. Cereb.
Cortex 27, 5303–5317. doi: 10.1093/cercor/bhw309
Eugène, E., Cluzeaud, F., Cifuentes-Diaz, C., Fricker, D., Le Duigou, C.,
Clemenceau, S., et al. (2014). An organotypic brain slice preparation from
adult patients with temporal lobe epilepsy. J. Neurosci. Methods 235, 234–244.
doi: 10.1016/j.jneumeth.2014.07.009
Goffin, K., Van Paesschen, W., and Van Laere, K. (2011). In vivo activation of
endocannabinoid system in temporal lobe epilepsy with hippocampal sclerosis.
Brain 134, 1033–1040. doi: 10.1093/brain/awq385
Hadjivassiliou, G., Martinian, L., Squier, W., Blumcke, I., Aronica, E., Sisodiya,
S. M., et al. (2010). The application of cortical layer markers in the evaluation
of cortical dysplasias in epilepsy. Acta Neuropathol. 120, 517–528. doi: 10.1007/
s00401-010-0686-x
Hess, E. J., Moody, K. A., Geffrey, A. L., Pollack, S. F., Skirvin, L. A., Bruno, P. L.,
et al. (2016). Cannabidiol as a new treatment for drug-resistant epilepsy in
tuberous sclerosis complex. Epilepsia 7, 1617–1624. doi: 10.1111/EPI.13499
Iﬄand, P. H., Baybis, M., Barnes, A. E., Leventer, R. J., Lockhart, P. J., and Crino,
P. B. (2018). DEPDC5 and NPRL3 modulate cell size, filopodial outgrowth, and
localization of mTOR in neural progenitor cells and neurons. Neurobiol. Dis.
114, 184–193. doi: 10.1016/j.nbd.2018.02.013
Iﬄand, P. H., and Crino, P. B. (2017). Focal cortical dysplasia: gene mutations,
cell signaling, and therapeutic implications. Annu. Rev. Pathol. Mech. Dis. 12,
547–571. doi: 10.1146/annurev-pathol-052016-100138
Jansen, L. A., Mirzaa, G. M., Ishak, G. E., O’Roak, B. J., Hiatt, J. B., Roden,
W. H., et al. (2015). PI3K/AKT pathway mutations cause a spectrum of brain
malformations from megalencephaly to focal cortical dysplasia. Brain 138,
1613–1628. doi: 10.1093/brain/awv045
Lim, J. S., Kim, W. I., Kang, H. C., Kim, S. H., Park, A. H., Park, E. K., et al. (2015).
Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading
to intractable epilepsy. Nat. Med. 21, 395–400. doi: 10.1038/nm.3824
Ljungberg, M. C., Bhattacharjee, M. B., Lu, Y., Armstrong, D. L., Yoshor, D.,
Swann, J. W., et al. (2006). Activation of mammalian target of rapamycin in
cytomegalic neurons of human cortical dysplasia. Ann. Neurol. 60, 420–429.
doi: 10.1002/ana.20949
Ludányi, A., Eross, L., Czirják, S., Vajda, J., Halász, P., Watanabe, M., et al.
(2008). Downregulation of the CB1 cannabinoid receptor and related molecular
elements of the endocannabinoid system in epileptic human hippocampus.
J. Neurosci. 28, 2976–2990. doi: 10.1523/JNEUROSCI.4465-07.2008
Maroso, M., Szabo, G. G., Kim, H. K., Alexander, A., Bui, A. D., Lee, S. H., et al.
(2016). Cannabinoid control of learning and memory through HCN Channels.
Neuron 89, 1059–1073. doi: 10.1016/j.neuron.2016.01.023
Mato, S., Del Olmo, E., and Pazos, A. (2003). Ontogenetic development of
cannabinoid receptor expression and signal transduction functionality in the
human brain. Eur. J. Neurosci. 17, 1747–1754. doi: 10.1046/j.1460-9568.2003.
02599.x
Meyuhas, O. (2015). Ribosomal protein S6 phosphorylation. Int. Rev. CellMol. Biol.
320, 41–73. doi: 10.1016/bs.ircmb.2015.07.006
Monory, K., Massa, F., Egertová, M., Eder, M., Blaudzun, H., Westenbroek, R., et al.
(2006). The Endocannabinoid system controls key epileptogenic circuits in the
hippocampus. Neuron 51, 455–466. doi: 10.1016/j.neuron.2006.07.006
Morcillo-Suarez, C., Alegre, J., Sangros, R., Gazave, E., de Cid, R., Milne, R., et al.
(2008). SNP analysis to results (SNPator): a web-based environment oriented
to statistical genomics analyses upon SNP data. Bioinformatics 24, 1643–1644.
doi: 10.1093/bioinformatics/btn241
Mulder, J., Aguado, T., Keimpema, E., Barabás, K., Ballester Rosado, C. J.,
Nguyen, L., et al. (2008). Endocannabinoid signaling controls pyramidal cell
specification and long-range axon patterning. Proc. Natl. Acad. Sci. U.S.A. 105,
8760–8765. doi: 10.1073/pnas.0803545105
Najm, I. M., Sarnat, H. B., and Blümcke, I. (2018). Review: the international
consensus classification of focal cortical dysplasia - a critical update 2018.
Neuropathol. Appl. Neurobiol. 44, 18–31. doi: 10.1111/nan.12462
Orlova, K. A., Tsai, V., Baybis, M., Heuer, G. G., Sisodiya, S., Thom, M., et al. (2010).
Early progenitor cell marker expression distinguishes type II from type I focal
cortical dysplasias. J. Neuropathol. Exp. Neurol. 69, 850–863. doi: 10.1097/NEN.
0b013e3181eac1f5
Puighermanal, E., Marsicano, G., Busquets-Garcia, A., Lutz, B., Maldonado, R.,
and Ozaita, A. (2009). Cannabinoid modulation of hippocampal long-term
memory is mediated by mTOR signaling. Nat. Neurosci. 12, 1152–1158. doi:
10.1038/nn.2369
Ricos, M. G., Hodgson, B. L., Pippucci, T., Saidin, A., Ong, Y. S., Heron, S. E., et al.
(2016). Mutations in the mammalian target of rapamycin pathway regulators
NPRL2 and NPRL3 cause focal epilepsy.Ann. Neurol. 79, 120–131. doi: 10.1002/
ana.24547
Smith, D. R., Stanley, C. M., Foss, T., Boles, R. G., and McKernan, K. (2017). Rare
genetic variants in the endocannabinoid system genes CNR1 and DAGLA are
associated with neurological phenotypes in humans. PLoS One 12:e0187926.
doi: 10.1371/journal.pone.0187926
Frontiers in Pharmacology | www.frontiersin.org 12 January 2019 | Volume 9 | Article 1508
fphar-09-01508 January 2, 2019 Time: 18:19 # 13
García-Rincón et al. Cannabinoid Signaling in Focal Cortical Dysplasia
Soltesz, I., Alger, B. E., Kano, M., Lee, S.-H., Lovinger, D. M., Ohno-Shosaku, T.,
et al. (2015). Weeding out bad waves: towards selective cannabinoid
circuit control in epilepsy. Nat. Rev. Neurosci. 16, 264–277. doi: 10.1038/
nrn3937
Thiele, E. A., Marsh, E. D., French, J. A., Mazurkiewicz-Beldzinska, M., Benbadis,
S. R., Joshi, C., et al. (2018). Cannabidiol in patients with seizures associated
with lennox-gastaut syndrome (GWPCARE4): a randomised, double-blind,
placebo-controlled phase 3 trial. Lancet 391, 1085–1096. doi: 10.1016/S0140-
6736(18)30136-3
Wang, X., Dow-Edwards, D., Keller, E., and Hurd, Y. L. (2003). Preferential
limbic expression of the cannabinoid receptor mRNA in the human
fetal brain. Neuroscience 118, 681–694. doi: 10.1016/S0306-4522(03)
00020-4
Yao, K., Duan, Z., Zhou, J., Li, L., Zhai, F., Dong, Y., et al. (2016).
Clinical and immunohistochemical characteristics of type II and type I
focal cortical dysplasia. Oncotarget 7, 76415–76422. doi: 10.18632/oncotarget.
13001
Zurolo, E., Iyer, A. M., Spliet, W. G. M., Van Rijen, P. C., Troost, D., Gorter,
J. A., et al. (2010). CB1 and CB2 cannabinoid receptor expression during
development and in epileptogenic developmental pathologies. Neuroscience
170, 28–41. doi: 10.1016/j.neuroscience.2010.07.004
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 García-Rincón, Díaz-Alonso, Paraíso-Luna, Ortega, Aguareles,
de Salas-Quiroga, Jou, de Prada, Martínez-Cerdeño, Aronica, Guzmán, Pérez-
Jiménez and Galve-Roperh. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 13 January 2019 | Volume 9 | Article 1508
